The potential off-label risks of BMP-2 have been documented in the literature and include: ectopic bone formation [26], swelling/hematoma [27], neoplasia [28], and wound problems; [29] this should be taken into consideration when using these therapies off-label. This evidence concerns the gene BMP2 and neoplasm.